News

Findings from the ECHELON-3 trial supported the approval of brentuximab vedotin plus lenalidomide and rituximab for relapsed/refractory LBCL.

Results from the PEACOCC trial warrant further investigation into treatment with pembrolizumab in patients with previously treated CCGC.

Serial CTRS, an AI-powered tool, has been granted FDA breakthrough device designation for classifying patients with NSCLC.

Envafolimab plus suvemcitug and FOLFIRI showed early efficacy and manageable safety in MSS/pMMR colorectal cancer, according to phase 2 trial data.

Lerociclib plus fulvestrant demonstrated a progression-free survival (PFS) advantage across all patient subgroups with HR–positive, HER2–negative advanced breast cancer.

The FDA has granted breakthrough device designation to the ACR-368 OncoSignature assay for use in endometrial cancer.

Erica S. Doubleday, MS, FNP-C, BSN, RN, illustrated the importance of consistent care to identify AEs like interstitial lung disease in patients with cancer.

In a phase 1 trial, all 9 patients with renal cell carcinoma treated with a neoantigen-targeting personalized cancer vaccine showed no recurrence at data cutoff.

After a phase 3 study showed a promising pCR rate with HLX11, the pertuzumab biosimilar’s BLA has been accepted for review by the FDA.

More excellent responses occurred for patients with low-risk thyroid cancer who had thyroidectomies without radioiodine vs treatment with radioiodine.

Thermal ablation was associated with no treatment-related deaths and fewer AEs compared to surgical resection in patients with CRC liver metastases.

Adolescent and young adult survivors of cancer face increased substance use risks due to developmental delays, limited support, and coping mechanisms, necessitating targeted prevention.

The FDA has approved a companion diagnostic to determine if patients with HR-positive, HER2-ultralow metastatic breast cancer are eligible for T-DXd treatment.

In BRAF V600E-mutant metastatic colorectal cancer, encorafenib plus cetuximab and mFOLFOX6 improved PFS and OS compared with chemotherapy.

Erica S. Doubleday, MS, FNP-C, BSN, RN, explains AEs commonly associated with use of trastuzumab deruxtecan.

January's FDA oncology approvals offer new treatment options for breast cancer, mantle cell lymphoma, and other malignancies.

Zipalertinib demonstrated efficacy in pretreated NSCLC with EGFR exon 20 insertion mutations, meeting the primary endpoint of ORR in the REZILIENT1 study.

Azenosertib (ZN-c3) demonstrated activity as a single agent in heavily pretreated patients with platinum-resistant, cyclin E1-positive ovarian cancer.

Inavolisib in combination with palbociclib and fulvestrant improved overall survival compared to palbociclib and fulvestrant alone in patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer.

Patients with relapsed ovarian cancer who had germline or somatic BRCA mutations saw greater OS with olaparib, according to data from the LIGHT trial.

Sintilimab with neoadjuvant chemoradiotherapy enhanced pCR rates in resectable, locally advanced esophageal squamous cell carcinoma.

The association of CAR T-cell therapies with second primary cancers warrants the development and examination of mitigation strategies for these toxic effects.

The combination of tislelizumab, irinotecan, paclitaxel, oxaliplatin, and 5-FU/leucovorin demonstrated promising efficacy and manageable safety in gastric and GEJ cancers.

Erica S. Doubleday, MS, FNP-C, BSN, RN, outlined upcoming approvals and care options for providers to expect in the breast cancer space.

The addition of trastuzumab and pertuzumab to chemotherapy was associated with increased toxicity in patients with HER2-positive gastric cancers enrolled in the INNOVATION trial.

La-Urshalar Brock, FNP-BC, CNM, RNFA, spoke about the oncology nurse’s and APP’s roles in managing chemotherapy-induced peripheral neuropathy in patients with breast cancer.

Managing weight loss with telotristat ethyl in patients with metastatic pancreatic ductal adenocarcinoma may improve survival, although further research is needed.

T-DXd has received FDA approval for the treatment of unresectable or metastatic HR+, HER2-low/-ultralow breast cancer in patients whose disease progressed on prior endocrine therapy in the metastatic setting.

Phone calls to follow up with patients with locally advanced esophageal squamous cell carcinoma while at home may reduce AEs like stomatitis before the first outpatient clinic visit.

Phase 2 findings show clinical responses and improved survival with evorpacept in patients with HER2-positive gastric/gastroesophageal cancer.